About the Journal

 

About the Journal

 

The European Journal of Clinical and Experimental Medicine (Eur J ClinExp Med) is an open access journal, and all articles are free to access, download, share, and re-use.The Eur J ClinExp Med is a peer-reviewed, international scientific journal that publishes full-length articles on topics within medical science. The journal welcomes submissions of articles on current advances in life and health sciences, clinical and experimental medicine, and related disciplines.

 

Open access and creative commons

All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0 [ https://creativecommons.org/licenses/by/4.0/?fbclid=IwAR3SIGSocnCk33VISbAE5hNKOdxvkYfgLING2JOtLF8pY_aOWxUOcoZQujI] . If you submit your paper for publication by the Eur J ClinExp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J ClinExp Med content can be mined without barriers for the research needs.

 

Article processing charges

The Eur J ClinExp Med is an open access journal and does not levy an article processing charge. There are no submission, color, or page charges for all article types.

 

Copyright Statement

Authors of articles published in the Eur J ClinExp Med retain copyright on their articles, except for any third-party images and other materials added by the Eur J ClinExp Med which are subject to copyright of their respective owners. Authors are therefore free to disseminate and re-publish their articles, subject to any requirements of third-party copyright owners and subject to the original publication being fully cited. Visitors may also download and forward articles subject to the citation requirements. The ability to copy, download, forward or otherwise distribute any materials is always subject to any copyright notices displayed. Copyright notices must be displayed prominently and may not be obliterated, deleted or hidden, totally or partially.

Ethics in publishing

The Eur J ClinExp Medtakes responsibility of enforcing rigorous peer-review together with strict ethical policies and standards to ensure to add high quality scientific works to the field of scholarly publication. Unfortunately, cases of plagiarism, data falsification, inappropriate authorship credit, and the like, do arise. The Eur J ClinExp Medtakes such publishing ethics issues very seriously and our editors are trained to proceed in such cases with a zero tolerance policy. The Eur J ClinExp Medis a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) [https://publicationethics.org/].

Editorial and submission policies

 

When you submit a manuscript to the Eur J ClinExp Med we will take it to imply that the manuscript has not already been published or submitted elsewhere. If similar or related work has been published or submitted elsewhere, then you must provide a copy of this work with the submitted manuscript. You may not submit your manuscript elsewhere while it is under consideration in theEur J ClinExp Med. If the manuscript includes personal communications, please provide a written statement of permission from any person who is quoted. Permission by email is acceptable.

We reserve the right to reject a paper even after it has been accepted if it becomes apparent that there are serious problems with its scientific content, or our publishing policies have been violated.

 

Author responsibilities

Authorship provides credit for a researcher’s contributions to a study and carries accountability. Authors are expected to fulfil the criteria below (adapted from McNutt et al., Proceedings of the National Academy of Sciences, 2018, 201715374; DOI: 10.1073/pnas.1715374115):

  • Each author is expected to have made substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data; or the creation of new software used in the work; or have drafted the work or substantively revised it
  • AND to have approved the submitted version (and any substantially modified version that involves the author's contribution to the study);
  • AND to have agreed both to be personally accountable for the author's own contributions and to ensure that questions related to the accuracy or integrity of any part of the work, even ones in which the author was not personally involved, are appropriately investigated, resolved, and the resolution documented in the literature.

The Eur J ClinExp Meddoes not require all authors of a research paper to sign the cover letter upon submission, nor do they impose an order on the list of authors. Submission to the Eur J ClinExp Med is taken by the publication to mean that all the listed authors have agreed to all of the contents. The corresponding (submitting) author is responsible for having ensured that this agreement has been reached, and for managing all communication between the publication and all co-authors, before and after publication.

Author contributions statements

Authors are required to include a statement of responsibility in the manuscript (at the end of the main text, before the 'References' section) that specifies the contribution of every author. For articles with several authors, a short paragraph specifying their individual contributions must be provided. The following statements should be used "Conceptualization, X.X. and Y.Y.; Methodology, X.X.; Software, X.X.; Validation, X.X., Y.Y. and Z.Z.; Formal Analysis, X.X.; Investigation, X.X.; Resources, X.X.; Data Curation, X.X.; Writing – Original Draft Preparation, X.X.; Writing – Review & Editing, X.X.; Visualization, X.X.; Supervision, X.X.; Project Administration, X.X.; Funding Acquisition, Y.Y.”.

Corresponding author – responsibilities

The corresponding (submitting) author is solely responsible for communicating with the Eur J ClinExp Med and for managing communication between co-authors. Before submission, the corresponding author ensures that all authors are included in the author list, its order has been agreed by all authors, and that all authors are aware that the paper was submitted.

A confidential process

The Eur J ClinExp Medtreats the submitted manuscript and all communication with authors and referees as confidential. Authors must also treat communication with the Eur J ClinExp Medas confidential: correspondence with the Eur J ClinExp Med, referee reports and other confidential material must not be posted on any website or otherwise publicized without prior permission from the Eur J ClinExp Medpublishing team, regardless of whether or not the submission is eventually published. Our policies about posting preprints and post prints, and about previous communication of the work at conferences or as part of a personal blog or of an academic thesis, are described in the Confidentiality section.

Referee suggestions

During the submission process, please suggest three potential reviewers (names and institutional e-mail addresses) with the appropriate expertise to review the manuscript, but please keep in mind that we are not obliged to follow these recommendations. The proposed referees should neither be current collaborators of the co-authors nor have published with any of the co-authors of the manuscript within the last five years. Proposed reviewers should be from different institutions to the authors. You may suggest reviewers from among the authors that you frequently cite in your paper.  You may also name a limited number of scientists who should not review your paper (up to 3 named individuals or laboratories); these exclusions will be honored. The decision of the Editorial Board Member on the choice of referees is final.

Ethics, use of experimental animals, and human participants

For articles in the Eur J ClinExp Medreporting experiments on live vertebrates and/or higher invertebrates, the methods section must include a statement: (i) identifying the institutional and/or licensing committee approving the experiments, including any relevant details; (ii) confirming that all experiments were performed in accordance with relevant guidelines and regulations.

For research involving human participants, authors must identify the committee that approved the research, confirm that all research was performed in accordance with relevant guidelines/regulations, and include in their manuscript a statement confirming that informed consent was obtained from all participants and/or their legal guardians.

Authors may be required to submit, on request, a statement from the research ethics committee or institutional review board indicating approval of the research.

Competing interests policy

In the interests of transparency and to help readers to form their own judgements of potential bias, authors must declare any competing financial and/or non-financial interests in relation to the work described. For the purposes of this policy, competing interests are defined as financial and non-financial interests that could directly undermine, or be perceived to undermine, the objectivity, integrity and value of a publication, through a potential influence on the judgements and actions of authors with regard to objective data presentation, analysis and interpretation. Examples of potential competing interests include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding.

Competing interests statement format guidelines

The statement included in the article file must be explicit and unambiguous, describing any potential competing interest (or lack thereof) for EACH contributing author.

Examples of declarations are:

  • Competing interests: The author(s) declare no competing interests.
  • Competing interests: Dr X's work has been funded by A. He has received compensation as a member of the scientific advisory board of B and owns stock in the company. He also has consulted for C and received compensation. Dr Y and Dr Z declare no potential conflict of interest.
  • Competing interests: “This work was supported by the [Funding Agency] under Grant [number].”

 

Peer-reviewers

The Eur J ClinExp Medinvites peer-reviewers to exclude themselves in cases where there is a significant conflict of interest, financial or otherwise. However, just as financial interests need not invalidate the conclusions of an article, nor do they automatically disqualify an individual from evaluating it. We ask peer-reviewers to inform the editors of any related interests, including financial interests as defined above that might be perceived as relevant. Editors will consider these statements when weighing peer-reviewers' recommendations.

Availability of materials and data

In order to maintain the integrity, transparency and reproducibility of research records, authors are encouraged to make their experimental and research data openly available either by depositing into data repositories or by publishing the data and files as supplementary information in this journal.

Data may be deposited with specialized service providers or institutional/subject repositories, preferably those that use the DataCite mechanism. Large data sets and files greater than 60 MB must be deposited in this way. For a list of other repositories specialized in scientific and experimental data, please consult databib.org or re3data.org. The data repository name, link to the data set (URL) and accession number, doi or handle number of the data set must be provided in the paper. The journal Data also accepts submissions of data set papers.

Data availability statement format guidelines

The statement should be provided as a separate section (titled 'Data Availability') at the end of the main text, before the 'References' section. Data availability statements should include, where applicable, accession codes, other unique identifiers and associated web links for publicly available datasets, and any conditions for access of non-publicly available datasets. Where figure source data are provided, statements confirming this should be included in data availability statements. Depending on the data described in the manuscript, data availability statements commonly take one of the following forms, or can be a composite of the statements below:

  • The datasets generated during and/or analyzed during the current study are available in the [NAME] repository, [PERSISTENT WEB LINK TO DATASETS].
  • The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.
  • All data generated or analyzed during this study are included in this published article (and its Supplementary Information files).
  • The datasets generated during and/or analyzed during the current study are not publicly available due to [REASON(S) WHY DATA ARE NOT PUBLIC] but are available from the corresponding author on reasonable request.
  • No datasets were generated or analyzed during the current study.
  • The data that support the findings of this study are available from [THIRD PARTY NAME] but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of [THIRD PARTY NAME].

Correction and retraction policy

The Eur J ClinExp Medoperates the following policy for making corrections to its peer-reviewed content.

Publishable amendments must be represented by a formal online notice because they affect the publication record and/or the scientific accuracy of published information. Where these amendments concern peer-reviewed material, they fall into one of four categories: Publisher Correction (formerly Erratum), Author Correction (formerly Corrigendum), Retraction or Addendum.

Publisher Correction (formerly Erratum). Notification of an important error made by the journal that affects the publication record or the scientific integrity of the paper or the reputation of the authors or the journal.

Author Correction (formerly Corrigendum). Notification of an important error made by the author(s) that affects the publication record or the scientific integrity of the paper, or the reputation of the authors or the journal.

Retraction. Notification of invalid results. All co-authors must sign a Retraction specifying the error and stating briefly how the conclusions are affected, and submit it for publication. In cases where co-authors disagree, the in-house editors may seek advice from independent referees and impose the type of amendment that seems most appropriate, noting the dissenting author(s) in the text of the published version.

Addendum. Notification of additional information. Addenda are published when the in-house editors decide that the addendum is crucial to the reader's understanding of a significant part of the published contribution.

Peer-review process

 

Initial checks

Once submitted, your manuscript will be assigned to a member of our Editorial Board, who will read the paper and decide whether it is appropriate for the journal. Manuscripts that are within scope and seem, on initial assessment, to be technically sound and scientifically valid, will be sent to external reviewers. Copies of any papers containing similar or related work under consideration or in press at other journals must be included with the submission.

Manuscripts that do not fit the journal's ethics policy or do not meet the standards of the journal will be rejected before peer-review. Manuscripts that are not properly prepared will be returned to the authors for revision and resubmission.

Peer review

Once a manuscript passes the initial checks, it will be assigned to at least two independent experts for peer-review. Reviewers will be able to access your manuscript securely using our online system, whilst maintaining referee anonymity. A double-blind review is applied, where authors' identities are unknown to reviewers and vice versa. Peer review comments are confidential and will only be disclosed with the express agreement of the reviewer.

Editorial Decision

After considering the reviewer reports the Editorial Board Member will make one of the following decisions:

  • Accept outright,
  • Request a minor revision, where authors revise their manuscript to address specific concerns,
  • Request a major revision, where authors revise their manuscript to address significant concerns and perhaps undertake additional work,
  • Reject outright.

 

The final decision is made by the Editor-in-Chief.

Revisions

In cases where the referees or Editorial Board Member has requested changes to the manuscript, you will be invited to prepare a revision. The decision letter will specify a deadline for submission of a revised manuscript. Once resubmitted, the manuscript may then be sent back to the original referees or to new referees, at the Editorial Board Member's discretion.

A revised manuscript should be submitted via the revision link provided in the decision letter, and not as a new manuscript. The revision should also be accompanied by a point-by-point response to referees explaining how the manuscript has been changed. Please ensure that all issues raised have been addressed in the first round of revision. Where the authors disagree with a reviewer, they must provide a clear response.

Final submission and acceptance

When all editorial issues are resolved, your paper will be formally accepted for publication. Once accepted, the manuscript will undergo professional copy-editing, English editing, final corrections, pagination, and, publication on the http://www.ejcem.ur.edu.pl/. The Eur J ClinExp Medreserves the right to make the final decision about matters of style and the size of figures.

 

Appeals

Even in cases where the Eur J ClinExp Meddoes not invite resubmission of a manuscript, some authors may ask the Editorial Board to reconsider a rejection decision. These are considered appeals, which, by policy, must take second place to the normal workload. In practice, this means that decisions on appeals often take several weeks. Only one appeal is permitted for each manuscript, and appeals can only take place after peer review. Final decisions on appeals will be made by the Editorial Board Member handling the paper.

Decisions are reversed on appeal only if the relevant Editorial Board Member is convinced that the original decision was a serious mistake. Consideration of an appeal is merited if a referee made substantial errors of fact or showed evidence of bias, but only if a reversal of that referee's opinion would have changed the original decision. Similarly, disputes on factual issues need not be resolved unless they were critical to the outcome.

If an appeal merits further consideration, the Editorial Board Member may send the authors' response and the revised paper out for further peer review.

ORCID

The Eur J ClinExp Medsupports the use of ORCID. The Eur J ClinExp Medmandates ORCID iDs for all submitting authors; this is published on the final article to promote discoverability and credit. Please provide the ORCID iDs of the authors in the title page.

Submission guidelines

 

Submission Process

Manuscripts for the Eur J ClinExp Medshould be submitted online at https://mc04.manuscriptcentral.com/pmur. The submitting author, who is generally the corresponding author, is responsible for the manuscript during the submission and peer-review process. The submitting author must ensure that all eligible co-authors have been included in the author list (read the criteria to qualify for authorship) and that they have all read and approved the submitted version of the manuscript. To submit your manuscript, register and log in to the submission website. All co-authors can see the manuscript details in the submission system, if they register and log in using the e-mail address provided during manuscript submission.

Cover letter

A cover letter must be included with each manuscript submission. It should be concise and explain why the content of the paper is significant, placing the findings in the context of existing work and why it fits the scope of the journal. Confirm that neither the manuscript nor any parts of its content are currently under consideration or published in another journal. The names of proposed and excluded reviewers should be provided in the submission system, not in the cover letter.

Accepted File Formats

Authors must use Microsoft Word to prepare their manuscript. Please insert your tables, graphics (schemes, figures, etc.) in the main text after the paragraph of its first citation.

In most cases, we do not impose strict limits on word count or page number. However, we strongly recommend that you write concisely and stick to the following guidelines:

  • We encourage not exceeding 20 pages for original and review papers, and 8 pages for case reports of standard computer text (1800 signs on a page).
  • The main text should be no more than 4,500 words (not including Abstract, Methods, References and figure legends).
  • The title should be no more than 20 words.
  • The abstract should be no more than 250 words.
  • Recommended font: Times New Roman, 12 points.
  • Manuscript text should be double-spaced.  Do not format text in multiple columns.

 

Types of Publications

Manuscripts submitted to the Eur J ClinExp Medshould neither be published previously nor be under consideration for publication in another journal. The main article types are as follows:

Original research manuscripts. The journal considers all original research manuscripts provided that the work reports scientifically sound experiments and provides a substantial amount of new information.

Reviews. These provide concise and precise updates on the latest progress made in a given area of research. Systematic reviews should follow the PRISMA guidelines.

The Eur J ClinExp Medaccepts also the following types of submissions: case reports, letters to the editor, commentaries, book reviews, and reports from scientific meetings and conferences.

Reporting guidelines

The guidelines listed below should be followed where appropriate. Please use these guidelines to structure your article. Completed applicable checklists, structured abstracts and flow diagrams should be uploaded with your submission; these will be published alongside the final version of your paper.

Please refer to existing guidelines for reporting methodology; e.g.:

 

 

Manuscript Preparation

Your paper should consist of the following parts. Title page should be supplied as a separate file.

Research manuscripts should comprise:

  • Title page: Title, Author list, Affiliations, Abstract, Keywords.
  • Research manuscript sections: Introduction, Aim, Materials and Methods, Results, Discussion, Conclusions.
  • Back matter: Supplementary Materials, Acknowledgments, Author Contributions, Conflicts of Interest, References.

Research manuscript sections:

  • Introduction

State the objectives of the work and provide an adequate background, avoiding a detailed literature survey or a summary of the results.

  • Material and methods

Provide sufficient details to allow the work to be reproduced by an independent researcher. Methods that are already published should be summarized, and indicated by a reference. If quoting directly from a previously published method, use quotation marks and also cite the source. Any modifications to existing methods should also be described.

  • Results

Results should be clear and concise. The section may be divided into subsections, each with a concise subheading. Tables and figures central to the study should be included in the main paper. Do not use the term “significant” unless p-values are provided. Show p-values to 2 or 3 decimal places. The Results section should be written in past tense.

  • Discussion

This should explore the significance of the results of the work, not repeat them. Avoid extensive citations and discussion of published literature.

  • Conclusions

Summarize the work’s findings, state their importance, and possibly recommend further research.

 

Review manuscripts should comprise:

  • Title page: Title, Author list, Affiliations, Abstract, Keywords
  • Literature review sections
  • Back matter: Supplementary Materials, Acknowledgments, Author Contributions, Conflicts of Interest, References.

Structured reviews and meta-analyses should use the same structure as research articles and ensure they conform to the PRISMA guidelines.

 

Case reports should comprise:

  • Title page: Title, Author list, Affiliations, Abstract, Keywords
  • Case reports should include a succinct introduction about the general medical condition or relevant symptoms that will be discussed in the case report; the case presentation including all of the relevant de-identified demographic and descriptive information about the patient(s), and a description of the symptoms, diagnosis, treatment, and outcome; a discussion providing context and any necessary explanation of specific treatment decisions; a conclusion briefly outlining the take-home message and the lessons learned.
  • Back matter: Supplementary Materials, Acknowledgments, Author Contributions, Conflicts of Interest, References.

Please note that tables with captions and figures with captions should be should be inserted immediately after the first paragraph in which they are cited.

 

Language Style

Manuscripts must be submitted in English (American or British usage is accepted, but not a mixture of these).

 

Title page

These sections should appear in all manuscript types:

Title: The title of your manuscript should be concise and informative. It should identify if the study reports (human or animal) trial data, or is a systematic review, meta-analysis or replication study. When gene or protein names are included, the abbreviated name rather than full name should be used.

Author List and Affiliations: Authors' full first and last names must be provided. For each affiliation provide the details in the following order: department, institution, city, country. If available, the e-mail address of each author should also be provided. At least one author should be designated as corresponding author, and his or her email address and other details should be included at the end of the affiliation section.

Abstract: The abstract should be a total of about 250 words maximum. The abstract should be a single paragraph and should follow the style of structured abstracts: Background: Place the question addressed in a broad context and highlight the purpose of the study; Methods: Describe briefly the main methods or treatments applied. Include any relevant preregistration numbers, and species and strains of any animals used. Results: Summarize the article's main findings; and Conclusion: Indicate the main conclusions or interpretations.

Keywords: Three to six pertinent keywords need to be added after the abstract in alphabetical order. We recommend that the keywords are specific to the article, yet reasonably common within the subject discipline.

 

Back Matter

Supplementary Materials: Describe any supplementary material published online alongside the manuscript (figure, tables, video, spreadsheets, etc.). Please indicate the name and title of each element as follows Figure S1: title, Table S1: title, etc.

Acknowledgments: All sources of funding of the study should be disclosed.

Author Contributions: Authors must supply an Author Contribution Statement as described in the  Author contributions statements section.

Conflicts of Interest: Authors must supply a competing interests statement. For more details please see Competing interests policy.

Data availability:Authors must include a Data Availability Statement in all submitted manuscripts (at the end of the main text, before the References section); see Data availability statement format guidelines section for more information.

References: References must be numbered in order of appearance in the text (including table captions and figure legends) and listed individually at the end of the manuscript. We recommend preparing the references with a bibliography software package, such as EndNote, Reference Manager or Zotero to avoid typing mistakes and duplicated references.

References style

We don’t copy edit your references. Therefore, it’s essential you format them correctly, as they will be linked electronically to external databases where possible. References should be prepared according to the American Medical Association style.

Examples: The degree of respiratory muscles fatigue depends on the applied exercise protocol and the research group's fitness level.1,2  The greatest load with which a patient continues breathing for at least one minute is a measure of inspiratory muscles strength.3 Diabetes mellitus is associated with a high risk of foot ulcers.4-6

A citation should contain a maximum of 6 authors. When an article has more than six authors, only the first three names should be given by adding 'et al.' If the source does not have any authors, the citation should begin with the title.

Journal titles should be given in brief according to the Index Medicus standard.

The number of sources cited for a review article should be between 40 and 50, and from 20 to 40 for other articles. A minimum of 50 % of literature should come from the last 5 years.

The following are examples of individual citations made according to the required rules of editing and punctuation:

  • Article from a journal, number of authors from 1 to 6 

Author AA, Author BB, Author CC. Title of article. Abbreviated Journal Title. Year;Volume(Issue):Page-Page.

Lee JC, Seo HG, Lee WH, Kim HC, Han TR, Oh BM. Computer-assisted detection of swallowing difficulty. Comput Methods Programs Biomed. 2016;134(2):72-78.

Wolf ZR. Nursing practice breakdowns: Good and bad nursing. Medsurg Nursing. 2012;21(1):16-36.

  • Article from a journal, number of authors more than 6              

Author AA, Author BB, Author CC, et al. Title of article. Abbreviated Journal Title. Year;Volume (Issue):Page-Page.

Gonzalez ME, Martin EE, Anwar T, et al. Mesenchymal stem cell-induced DDR2 mediates stromal-breast cancer interactions and metastasis growth. Cell Rep. 2017;18:1215-1228.

Jordan J, Toplak H, Grassi G, et al. Joint statement of the European Association for the Study of Obesity and the European Society of Hypertension: obesity and heart failure. J Hypertens. 2016;34:1678-1688.

  • Article from an online journal: DOI      

Author AA, Author BB. Title of article. Abbreviated Journal Title. Year;Volume(Issue):Page-Page. doi:xx.xxxx/xxxxxxxxxxxxxx

Coppinger T, Jeanes YM, Hardwick J, Reeves S. Body mass, frequency of eating and breakfast consumption in 9-13-year-olds. J Hum Nutr Diet. 2012;25:43-49. doi: 10.1111/j.1365-277X.2011.01184.x.

Cogulu O, Schoumans J, Toruner G, Demkow U, Karaca E, Durmaz AA. Laboratory Genetic Testing in Clinical Practice 2016. Biomed Res Int. 2017;2017:5798714. doi: 10.1155/2017/5798714.

  • Websites           

Webpage title. Name of Website. URL. Published or Updated date. Accessed date.

Cholera in Haiti. Centers for Disease Control and Prevention Web site. http://www.cdc.gov/haiticholera/. Published October 22, 2010. Updated January 9, 2012. Accessed February 1, 2012.

Address double burden of malnutrition: WHO. World Health Organization site. http://www.searo.who.int/mediacentre/releases/2016/1636/en/. Accessed February 2, 2017.

  • Book    

Author AA, Author BB. Title of Work. Location: Publisher; Year:Page-Page

Doane GH, Varcoe C. Family Nursing as Relational Inquiry: Developing Health– Promoting Practice. Philadelphia, PA: Lippincott Williams & Wilkins; 2005:25-28.

London ML, Ladewig PW, Ball JW, et al. Maternal & Child Nursing Care. Upper Saddle River, NJ: Pearson Education; c2011:101-103.

  • Chapter in a book         

Author AA. Title of Work. Editor AA, Editor BB, eds. Location: Publisher; Year:PagePage.

Goodman LS, Brunton LL, Chabner B, Knollmann BC. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. Brunton LL, ed. New York, NY: McGraw-Hill; 2011:99.

NOTE: The editorial board requires consistent and carefully made references prepared according to the above-mentioned AMA standards. Otherwise, the work will be sent back to the authors.

 

Preparing Figures, Schemes and Tables

File for Figures and Schemes must be provided during submission and at a sufficiently high resolution (minimum 1000 pixels width/height, or a resolution of 300 dpi or higher). Common formats are accepted, however, TIFF, JPEG, EPS and PDF are preferred.

All Figures, Schemes and Tables should be inserted into the main text close to their first citation and must be numbered following their number of appearance (Figure 1, Scheme I, Figure 2, Scheme II, Table 1, etc.).

All Figures, Schemes and Tables should have a short explanatory title and caption.

Tables should present new information rather than duplicating what is in the text. Readers should be able to interpret the table without reference to the text.

All table columns should have an explanatory heading. To facilitate the copy-editing of larger tables, smaller fonts may be used, but no less than 8 pt. in size.Please supply editable tables in appropriate place in the main text. Do not submit your tables in separate files.

Abbreviations

The journal requires using only standard abbreviations. Abbreviations should be defined in parentheses the first time they appear in the abstract, main text and in figure or table captions and used consistently thereafter. Ensure consistency of abbreviations throughout the article. Keep abbreviations to a minimum.

SI Units

SI Units (International System of Units) should be used. Imperial, US customary and other units should be converted to SI units whenever possible.